Cancer gene therapy: fringe or cutting edge?

[1]  T. Ratliff.  Robust prostate-specific expression for the targeted gene therapy based on the human kallikrein 2 promoter. , 2002, The Journal of urology.

[2]  N. Senzer,et al.  Virus-mediated killing of cells that lack p53 activity. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[3]  R. Mansel,et al.  A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  F. McCormick.  New-age drug meets resistance , 2001, Nature.

[5]  R. Martuza,et al.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions , 2001, Nature Medicine.

[6]  A. Braithwaite,et al.  Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway? , 2001, Journal of Virology.

[7]  F. McCormick,et al.  Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. , 2001, Cancer research.

[8]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[9]  D. Curiel,et al.  Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. , 2001, Cancer research.

[10]  W. Wold,et al.  Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy , 2001, Journal of Virology.

[11]  S. Hirono,et al.  Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. , 2001, Cancer research.

[12]  J. Lebkowski,et al.  The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters , 2001, Gene Therapy.

[13]  C. Harley,et al.  Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. , 2001, Cancer research.

[14]  Peter K. Sorger,et al.  A role for the Adenomatous Polyposis Coli protein in chromosome segregation , 2001, Nature Cell Biology.

[15]  H. Clevers,et al.  Mutations in the APC tumour suppressor gene cause chromosomal instability , 2001, Nature Cell Biology.

[16]  R. Iggo,et al.  Replicating Adenoviruses That Target Tumors with Constitutive Activation of the wnt Signaling Pathway , 2001, Journal of Virology.

[17]  T. Kijima,et al.  Adenovirus‐mediated gene therapy specific for small cell lung cancer cells using a Myc‐Max binding motif , 2001, International journal of cancer.

[18]  A. Nakagawara,et al.  Expression of herpes simplex virus‐thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells , 2001, International journal of cancer.

[19]  K. Ulbrich,et al.  Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies , 2001, Gene Therapy.

[20]  R. MacKie,et al.  Intralesional injection of herpes simplex virus 1716 in metastatic melanoma , 2001, The Lancet.

[21]  T. Tadakuma,et al.  Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. , 2001, Cancer research.

[22]  V. W. Lui,et al.  Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Rusheng Zhang,et al.  Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. , 2001, Thyroid : official journal of the American Thyroid Association.

[24]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Roth,et al.  Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts , 2001, International journal of radiation biology.

[26]  John Mendelsohn,et al.  The EGF receptor family as targets for cancer therapy , 2000, Oncogene.

[27]  J. Nemunaitis,et al.  Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice , 2000, Gene Therapy.

[28]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[29]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[30]  Michael A Davies,et al.  MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells , 2000, Oncogene.

[31]  S. Ylä-Herttuala,et al.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. , 2000, Human gene therapy.

[32]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[33]  K. Brand,et al.  Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. , 2000, Cancer research.

[34]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[35]  B. Hann,et al.  Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) , 2000, Nature Medicine.

[36]  C. Schnell,et al.  Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. , 2000, Human gene therapy.

[37]  M. Clarke,et al.  A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. , 2000, Human gene therapy.

[38]  J. Bergelson,et al.  The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. , 2000, Cancer research.

[39]  D. Brough,et al.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. , 2000, The Journal of clinical investigation.

[40]  H. Yamaue,et al.  Enhanced Selective Gene Expression by Adenovirus Vector Using Cre/loxP Regulation System for Human Carcinoembryonic Antigen-Producing Carcinoma , 2000, Oncology.

[41]  J. Gyuris,et al.  The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[43]  D. Yu,et al.  Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. , 2000, Human gene therapy.

[44]  W. Wold,et al.  Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein , 2000, Journal of Virology.

[45]  C. Morton,et al.  Construction of adenovirus for high level expression of small RNAs in mammalian cells , 2000, Molecular biotechnology.

[46]  S. Weitzman,et al.  Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach , 2000, Cancer Gene Therapy.

[47]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[48]  A. Maclean,et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.

[49]  D. Grimm,et al.  Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors , 2000, Cancer Gene Therapy.

[50]  F. McCormick,et al.  Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. , 2000, Journal of the National Cancer Institute.

[51]  K. Inoue,et al.  Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. , 2000, Cancer research.

[52]  R. Kuwano,et al.  The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. , 2000, Brain research. Molecular brain research.

[53]  D. Kallmes,et al.  Osteocalcin-directed gene therapy for prostate-cancer bone metastasis , 2000, World Journal of Urology.

[54]  G. Stamatoyannopoulos,et al.  Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector , 2000, Journal of Virology.

[55]  K. Scanlon,et al.  Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells , 2000, Cancer Gene Therapy.

[56]  Masato Nakamura,et al.  Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma , 2000, Cancer Gene Therapy.

[57]  Jin Cheng,et al.  Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme , 2000, Cancer Gene Therapy.

[58]  Cheng-Ta Yang,et al.  ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. , 2000, Cancer research.

[59]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[61]  Y. Nakamura,et al.  Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. , 1999, Cancer research.

[62]  D. Waxman,et al.  Cytochrome P450-based cancer gene therapy: recent advances and future prospects. , 1999, Drug metabolism reviews.

[63]  A. Sakurada,et al.  Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. , 1999, International journal of oncology.

[64]  M. Bewley,et al.  Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. , 1999, Science.

[65]  D. Kirn,et al.  Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects , 1999, Cancer Gene Therapy.

[66]  Careen K. Tang,et al.  Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. , 1999, Cancer research.

[67]  A. Houtsmuller,et al.  Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers , 1999, Gene Therapy.

[68]  X. Breakefield,et al.  Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. , 1999, Cancer research.

[69]  D. Louis,et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses , 1999, Nature Medicine.

[70]  M. Halks-Miller,et al.  Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. , 1999, Antisense & nucleic acid drug development.

[71]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[72]  M. Gnant,et al.  Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. , 1999, Cancer research.

[73]  S. Stass,et al.  Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. , 1999, Cancer research.

[74]  A. Berk,et al.  p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication , 1999, Journal of Virology.

[75]  G. Clayman,et al.  Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[77]  K. Sikora,et al.  Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  J. Yokota,et al.  Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16INK4A gene. , 1999, International journal of oncology.

[79]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[80]  Y. Nakamura,et al.  Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  W. Lee,et al.  RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[82]  R. Grand,et al.  The Replicative Capacities of Large E1B-Null Group A and Group C Adenoviruses Are Independent of Host Cell p53 Status , 1999, Journal of Virology.

[83]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[84]  A. Hengstermann,et al.  Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells , 1998, Journal of Virology.

[85]  F. Goodrum,et al.  p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection , 1998, Journal of Virology.

[86]  H. Mueller.  Tumor necrosis factor as an antineoplastic agent: pitfalls and promises , 1998, Cellular and Molecular Life Sciences CMLS.

[87]  W. Ramsey,et al.  Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. , 1998, Human gene therapy.

[88]  J. Roth,et al.  An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. , 1998, Cancer research.

[89]  P. Nisen,et al.  A glial-specific, repressible, adenovirus vector for brain tumor gene therapy. , 1998, Cancer research.

[90]  G. Demers,et al.  A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth. , 1998, Cancer gene therapy.

[91]  P. Wen,et al.  Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. , 1998, Human gene therapy.

[92]  T. Miyamoto,et al.  Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. , 1998, The Journal of urology.

[93]  J. H. Kim,et al.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. , 1998, Human gene therapy.

[94]  L. Ellis,et al.  Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.

[95]  I. W. Cheney,et al.  Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. , 1998, Cancer research.

[96]  S. Barsky,et al.  Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. , 1998, Anticancer research.

[97]  R. Crystal,et al.  Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma , 1998, Gene Therapy.

[98]  S. Brown,et al.  Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector – potential glioblastoma targeting , 1998, Gene Therapy.

[99]  X. Breakefield,et al.  Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. , 1998, Journal of the National Cancer Institute.

[100]  S. Srivastava,et al.  Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells , 1998, Oncogene.

[101]  D. Troyer,et al.  A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis , 1998, Molecular and Cellular Biology.

[102]  J. Bergelson,et al.  The Murine CAR Homolog Is a Receptor for Coxsackie B Viruses and Adenoviruses , 1998, Journal of Virology.

[103]  R. Kratzke,et al.  Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  P. Seth,et al.  A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. , 1997, Cancer gene therapy.

[105]  M. King,et al.  A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  D. Hallahan,et al.  Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. , 1997, Cancer research.

[107]  P. Wen,et al.  Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector , 1997, Nature Medicine.

[108]  A. Wellstein,et al.  Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation , 1997, Gene Therapy.

[109]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[110]  H. Kishima,et al.  Usefulness of a Mouse Myelin Basic Protein Promoter for Gene Therapy of Malignant Glioma: Myelin Basic Protein Promoter Is Strongly Active in Human Malignant Glioma Cells , 1997, Japanese journal of cancer research : Gann.

[111]  M. G. Bhat,et al.  Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. , 1997, The Journal of investigative dermatology.

[112]  C. Henschke,et al.  Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. , 1997, Human gene therapy.

[113]  E. Maxwell,et al.  Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. , 1997, Cancer gene therapy.

[114]  R. Fenton,et al.  Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. , 1996, Cancer research.

[115]  J. Roth,et al.  In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. , 1996, Anticancer research.

[116]  J. Roth,et al.  Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. , 1996, Cancer gene therapy.

[117]  D. Riley,et al.  Adenovirus–mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb+/− mice , 1996, Nature Medicine.

[118]  D. Kirn,et al.  Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.

[119]  H. Wakimoto,et al.  Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors. , 1996, Gastroenterology.

[120]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[121]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[122]  T. Sugimura,et al.  Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. , 1996, Human gene therapy.

[123]  K. Kinzler,et al.  Apoptosis and APC in colorectal tumorigenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[124]  N. Shao,et al.  Induction of apoptosis by the tumor suppressor protein BRCA1. , 1996, Oncogene.

[125]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[126]  C. Springer,et al.  Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. , 1995, European journal of cancer.

[127]  V. Knick,et al.  Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. , 1995, Cancer research.

[128]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[129]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[130]  Z. Bebők,et al.  Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. , 1994, Gene therapy.

[131]  J. Nevins.  Adenovirus E1A-dependent trans-activation of transcription. , 1990, Seminars in cancer biology.

[132]  F. Moolten.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.

[133]  Hong Zhang,et al.  Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. , 2001, Cancer research.

[134]  G. Pierce,et al.  Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[135]  P. Stiegler,et al.  RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. , 2001, Cancer research.

[136]  G. Cauet,et al.  Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach , 2001, Cancer Gene Therapy.

[137]  E. Morimoto,et al.  Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. , 2001, Anticancer research.

[138]  M. Halks-Miller,et al.  Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells , 2000, Gene Therapy.

[139]  酒井 佳夫.  Gene therapy for hepatocellular carcinoma using two recombinant adenovirus vectors with α-fetoprotein promoter and Cre/lox P system , 2000 .

[140]  S. Woo,et al.  Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase , 2000, Cancer Gene Therapy.

[141]  住友 賢哉.  Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16[INK4A] gene , 2000 .

[142]  O. Wildner,et al.  Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer , 1999, Gene Therapy.

[143]  C. Morton,et al.  Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. , 1998, Cancer research.

[144]  K. Dameron,et al.  The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. , 1994, Cold Spring Harbor symposia on quantitative biology.

[145]  J. Roth,et al.  High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. , 1994, Cancer gene therapy.

[146]  A. Berk,et al.  Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. , 1987, Virology.